Thomas J. Guzzo1, Matthew J. Resnick1, Daniel J. Canter1, Arturo Balandra1, Meredith R. Bergey1, Laurie Magerfl eisch1, John E. Tomaszewski2, David J. Vaughn3, S. Bruce Malkowicz1
Canadian Journal of Urology, Vol.17, No.6, pp. 5465-5471, 2010
Abstract Introduction: Radical cystectomy (RC) remains the gold standard treatment for patients with muscle-invasive bladder cancer. Unfortunately, a significant proportion of patients will have lymph node involvement at the time of RC. We set out to determine the impact of adjuvant cisplatin-based chemotherapy (AC) in a cohort of lymph node positive patients following RC.
Patients and methods: We reviewed our RC database and isolated patients with lymph node positive disease at the time of RC. Univariate and multivariable analysis was performed to identify predictors of poor outcome in patients receiving AC. Overall survival (OS), disease specific survival (DSS)… More >